Novartis’ ribociclib approved in Canada for early breast cancer
Health Canada has granted a notice of compliance for Novartis Canada’s Kisqali (ribociclib tablets) plus an aromatase inhibitor for the…
Health Canada has granted a notice of compliance for Novartis Canada’s Kisqali (ribociclib tablets) plus an aromatase inhibitor for the…
Scynexis has resumed dosing of its vaginal yeast infection drug Brexafemme (ibrexafungerp) in a Phase III trial after a 19-month…
The landscape of contraception for women has seen minimal change over the past 50 years, with successive generations often relying…
The European Commission (EC) has approved Daiichi Sankyo and AstraZeneca’s Enhertu (trastuzumab deruxtecan) for use as a single agent to…
Genmab has received approval from the Japan's Ministry of Health, Labour and Welfare for Tivdak (tisotumab vedotin) to treat advanced…
The US Food and Drug Administration (FDA) has approved GSK’s triazaacenaphthylene antibiotic, Blujepa (gepotidacin), for treating uncomplicated urinary tract infections…
Sermonix Pharmaceuticals and Regor Therapeutics have announced a strategic partnership to discover and develop therapeutics in the breast oncology area.…
The European Commission (EC) has approved GSK's Jemperli (dostarlimab) combined with chemotherapy that includes carboplatin and paclitaxel for the first-line…
IMPACT Therapeutics has received the China National Medical Products Administration (NMPA) marketing authorisation for Senaparib capsules to treat ovarian cancer.…
The European Commission (EC) has granted approval to Novartis' Kisqali (ribociclib), plus an aromatase inhibitor to treat early breast cancer…